- Home
- EIC vs ACIU Comparison
EIC vs ACIU Comparison
Compare EIC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIC | ACIU |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.3M | 213.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | EIC | ACIU |
|---|---|---|
| Price | $9.41 | $3.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $12.63 | $10.00 |
| AVG Volume (30 Days) | 149.3K | ★ 203.4K |
| Earning Date | 02-26-2026 | 04-29-2026 |
| Dividend Yield | ★ 13.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $635.38 |
| Revenue Next Year | N/A | $232.58 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.17 | $1.43 |
| 52 Week High | $14.83 | $4.00 |
Technical Indicators
Market Signals| Indicator | EIC | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 56.63 |
| Support Level | $9.25 | $2.56 |
| Resistance Level | $10.15 | $3.92 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 52.27 | 61.36 |
Price Performance
Historical ComparisonAbout EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.